Table 3.
Prognostic Models for All-Cause Mortality and HF Rehospitalization
| Predictors | All-cause mortality | HF rehospitalization | ||
|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | |
| Model 1 | ||||
| Control | Reference | – | Reference | – |
| Phase 1 | 0.963 (0.544–1.706) | 0.898 | 0.793 (0.516–1.221) | 0.292 |
| Phase 2 | 0.990 (0.556–1.764) | 0.973 | 0.444 (0.261–0.753) | 0.003 |
| ACE-i/ARB | 0.663 (0.416–1.056) | 0.084 | 0.546 (0.371–0.804) | 0.002 |
| ARNI | 0.354 (0.080–1.566) | 0.171 | 0.828 (0.271–2.532) | 0.740 |
| SGLT2 inhibitors | 0.615 (0.182–2.076) | 0.433 | 0.504 (0.171–1.483) | 0.213 |
| Tolvaptan | 3.489 (2.157–5.645) | <0.001 | 3.390 (2.309–4.977) | <0.001 |
| Albumin | 0.339 (0.2193–0.523) | <0.001 | 0.823 (0.569–1.191) | 0.302 |
| Model 2 | ||||
| Control | Reference | – | Reference | – |
| Phase 1 | 0.931 (0.501–1.730) | 0.820 | 0.886 (0.568–1.382) | 0.593 |
| Phase 2 | 1.163 (0.628–2.155) | 0.631 | 0.515 (0.296–0.894) | 0.018 |
| MAGGIC risk score | 1.060 (1.014–1.109) | 0.011 | 1.054 (1.018–1.090) | 0.003 |
| ARNI | 0.360 (0.076–1.698) | 0.197 | 1.138 (0.363–3.562) | 0.825 |
| SGLT2 inhibitors | 0.388 (0.089–1.683) | 0.206 | 0.461 (0.154–1.378) | 0.166 |
| Tolvaptan | 3.137 (1.856–5.302) | <0.001 | 2.791 (1.857–4.194) | <0.001 |
| Albumin | 0.439 (0.266–0.724) | <0.001 | 0.988 (0.657–1.486) | 0.953 |
| Sodium | 0.966 (0.904–1.032) | 0.309 | 0.965 (0.916–1.018) | 0.193 |
| BNP | 1.000 (1.000–1.000) | 0.109 | 1.000 (0.999–1.000) | 0.563 |
CI, confidence interval; HR, hazard ratio. Other abbreviations as in Table 1.